We use some essential cookies to make this website work.
We’d like to set additional cookies to understand how you use GOV.UK, remember your settings and improve government services.
We also use cookies set by other sites to help us deliver content from their services.
You have accepted additional cookies. You can change your cookie settings at any time.
You have rejected additional cookies. You can change your cookie settings at any time.
Departments, agencies and public bodies
News stories, speeches, letters and notices
Detailed guidance, regulations and rules
Reports, analysis and official statistics
Consultations and strategy
Data, Freedom of Information releases and corporate reports
Sets out deliverables and timelines to support the development of safe In Vitro Diagnostic (IVD) medical devices.
Using the Integrated Scientific Advice service from the Medicines and Healthcare products Regulatory Agency (MHRA) and National Institute for Health and Care Excellence (NICE).
Guidance on the importance of applying human factors to medical devices, so they are designed and optimised to minimise patient and user safety risks.
Examples of what manufacturers must report to the MHRA under the medical device vigilance system when incidents involving their devices occur in the UK.
Guidance on conditional marketing authorisations, exceptional circumstances marketing authorisations and national scientific advice.
Information about how to register your homeopathic medicinal product through the Simplified Homeopathic Registration Scheme or the UK Homeopathic National Rules Scheme
Information and advice on submitting a nutritional product to the Advisory Committee for Borderline Substances (ACBS).
The MHRA provides advice for Retailers and Producers of e-cigarette / vape products.
Recommendations for prescribing methadone and buprenorphine to people in treatment for opioid dependence in England.
The MHRA have implemented a dual strategy for a risk-adapted approach to clinical trials in the UK.
Device qualification and classification of ambient voice technology-enabled products that are medical devices intended to be placed on the market, or put into service, in Great Britain.
Information for wholesale dealer licence holders about the medicines put on the UK market for UK patients that they cannot export or hoard.
A list of individual human medicinal products under the new arrangements coming into effect on 1 January 2025 following agreement of the Windsor Framework.
The MHRA is part of the Access Consortium along with the Therapeutic Goods Administration, Health Canada, Health Sciences Authority of Singapore and Swissmedic.
Information on the implementation of labelling and packaging requirements for medicinal products for human use under the Windsor Framework.
Information and recommendations for manufacturers on the preparation and presentation of a post-market surveillance report (PMSR).
Information and recommendations for approved bodies on the presentation and review of a periodic safety update report (PSUR).
The locations for a Marketing Authorisation Holder (MAH) and a Qualified Person responsible for Pharmacovigilance (QPPV)
Guidance on how to submit changes to labelling and patient information leaflets to MHRA.
This guidance has been produced in collaboration with the UK Kidney Patient Safety Committee (KPSC), to summarise known safety issues with dialysis and continuous renal replacement therapy (CRRT) and describe what to do to m…
Do not include personal or financial information like your National Insurance number or credit card details.
To help us improve GOV.UK, we’d like to know more about your visit today. Please fill in this survey (opens in a new tab and requires JavaScript).